You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Claims for Patent: 7,803,931

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,803,931

Title:	Aptamer therapeutics useful in the treatment of complement-related disorders
Abstract:	The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Inventor(s):	Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
Assignee:	Astellas US LLC, Archemix LLC
Application Number:	US11/058,134
Patent Claims:	1. A compound consisting of the nucleotide sequence according to SEQ ID NO: 4 and having a PEG polymer of 40 kDa conjugated via a linker to the nucleotide sequence's 5′ end. 2. A compound having the PEGylated aptamer according to SEQ ID NO: 65. 3. A composition comprising a therapeutically effective amount of the compound of claim 1 or 2 or a salt thereof. 4. The composition of claim 3 comprising a pharmaceutically acceptable carrier or diluent. 5. The compound of claim 1, wherein the PEG polymer of 40 kDa is a branched PEG polymer of 40 kDa.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.